Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial
Phase of Trial: Phase II/III
Latest Information Update: 13 Apr 2014
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms NEAR
- 16 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Nov 2012 Interim early virological response rate results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.